. Essential fatty acid deficiency in mice is associated with hepatic steatosis and secretion of large VLDL particles. Am J Physiol Gastrointest Liver Physiol 288: G1150 -G1158, 2005. First published January 20, 2005 doi:10.1152/ajpgi.00456.2004.-Essential fatty acid (EFA) deficiency in mice decreases plasma triglyceride (TG) concentrations and increases hepatic TG content. We evaluated in vivo and in vitro whether decreased hepatic secretion of TG-rich very low-density lipoprotein (VLDL) contributes to this consequence of EFA deficiency. EFA deficiency was induced in mice by feeding an EFAdeficient (EFAD) diet for 8 wk. Hepatic VLDL secretion was quantified in fasted EFAD and EFA-sufficient (EFAS) mice using the Triton WR-1339 method. In cultured hepatocytes from EFAD and EFAS mice, VLDL secretion into medium was measured by quantifying [
DEVELOPMENT OF HEPATIC STEATOSIS is a well-established manifestation of essential fatty acid (EFA) deficiency in animal models. It was first described in 1958 in rats by Alfin-Slater and Bernick (3) and in 1970 by Fukazawa et al. (12) and Sinclair and Collins (43) . The excess lipid deposited in the liver during EFA deficiency can theoretically result from increased uptake of circulating lipids, enhanced de novo lipogenesis, decreased fatty acid oxidation, or decreased hepatic lipoprotein secretion, or from a combination of these. Increased hepatic lipogenesis and decreased fatty acid oxidation could indeed contribute, because polyunsaturated fatty acids are physiological suppressors of fatty acid synthesis (4, 31) through downregulation of SREBP1c (16, 42, 51) and inducers of hepatic fatty acid oxidation through activation of PPAR␣, respectively. The quantitative contribution of increased lipogenesis and decreased oxidation to EFA deficiency-induced hepatic steatosis has not been established. Whereas the effects of EFA deficiency on induction of hepatic steatosis are fairly consistent in the literature, the consequences for hepatic lipoprotein secretion and plasma lipid profiles are less clear. Fukazawa et al. (12) reported decreased triglyceride (TG) and phospholipid (PL) secretion from perfused livers of EFAdeficient (EFAD) rats. However, EFA deficiency has also been associated with enhanced hepatic TG secretion rates in rats (6, 19, 49, 50) . Similarly, data on lipoprotein clearance during EFA deficiency are equivocal. Activities of plasma lipoprotein lipase (LPL) (10, 43) and hepatic lipase (HL) were reported to be increased in EFAD rats by Nilsson et al. (36) , whereas Levy and colleagues (23, 27) described decreased plasma LPL activity in EFAD rats.
Recently, we characterized a mouse model for EFA deficiency in which hepatic TG levels are increased and plasma TG concentrations are decreased (48) . To preclude the confusion from isolated studies on EFA deficiency in different species and models, we have chosen to characterize this mouse model in detail. Previously, we reported characteristics of EFAD mice with respect to growth, intestinal fat absorption, bile formation, and fatty acid composition in specific organs (33, 47, 48) . In the present study, we investigated whether EFA deficiency affects hepatic very low-density lipoprotein (VLDL) secretion in mice in vivo and in isolated mouse hepatocytes in vitro. Our data indicate that EFA deficiency in mice does not quantitatively affect hepatic VLDL-TG secretion but increases VLDL particle size. We hypothesize that the clearance rate of these large lipoproteins is increased to yield low plasma TG levels.
MATERIALS AND METHODS

Materials
Triton WR-1339, Triton X-100, fatty acid-free BSA, oleic acid, and heptadecanoic acid were obtained from Sigma (St. Louis, MO). [ 3 H]glycerol was purchased from New England Nuclear (Boston, MA), glycerol tri-9,10(n)- [ 3 H]-labeled oleate was from Amersham Biosciences (Piscataway, NJ), and glycerol trioleate was from Fluka Chemie/Sigma-Aldrich (St. Louis, MO). SDS ready gels (4 -15%) were from Bio-Rad (Hercules, CA), heparin was obtained from Leo Pharma (Weesp, The Netherlands) and all cell culture materials were from Costar (Cambridge, MA).
Animals
Male wild-type mice with a free virus breed background were obtained from Harlan (Horst, the Netherlands). When starting the experimental diets, mice were ϳ8 wk old and were housed in a light-controlled (lights on 6 AM-6 PM) and temperature-controlled (21°C) facility with free access to tap water and standard laboratory chow (RMH-B; Arie Blok, Woerden, The Netherlands). The experimental protocols were approved by the Ethics Committee for Animal Experiments, Faculty of Medical Sciences, University of Groningen, The Netherlands.
Experimental Diets
The EFAD diet contained 20% energy protein, 46% energy carbohydrate and 34% energy fat, respectively, and had the following fatty acid composition: 41.4% mol palmitic acid (C16:0), 47.9% mol stearic acid (C18:0), 7.7% mol oleic acid (C18:1n-9) and 3% mol linoleic acid (C18:2n-6). An isocaloric EFA-sufficient (EFAS) diet was used as control diet, containing 20% energy protein, 43% energy carbohydrate and 37% energy fat with 32.1% mol C16:0, 5.5% C18:0, 32.2% mol C18:1n-9, and 30.2% C18:2n-6 custom synthesis, diet numbers 4141.08 (EFAD), and 4141.07 (EFAS), respectively (Arie Blok).
Experimental Procedures
Induction of EFA deficiency in mice. Mice were fed standard laboratory chow containing 6% weight fat from weaning, and switched to EFAD or EFAS diet at 8 wk of age. After 8 wk on EFAD or EFAS diet, 6 mice of each dietary group were anesthetized by halothane/NO 2 and a large blood sample was obtained by cardiac puncture for determination of plasma lipid levels, lipoprotein profile, and plasma and erythrocyte fatty acid composition. Blood was collected in heparinized tubes, and plasma and erythrocytes were separated by centrifugation at 2,400 rpm for 10 min (Eppendorf Centrifuge, Eppendorf, Germany). Fresh erythrocyte samples were hydrolyzed and methylated (35) for gas-chromatographic analysis of fatty acid profiles. After liver excision, tissue aliquots (30 mg) were immediately stored in liquid nitrogen for mRNA isolation. The remaining liver tissue was stored at Ϫ80°C until further analysis.
Fast protein liquid chromatography. For plasma lipoprotein size fractionation, 200 l of pooled plasma from EFAD-and EFAS-diet fed mice (n ϭ 6 for each group) were separated by fast protein liquid chromatography (FPLC) on a Superose 6 HR10/30 column (Amersham Pharmacia Biotech, Uppsala, Sweden). TG, PL, and cholesterol concentrations in the obtained fractions (0.5 ml) were measured as described in Analytical Techniques.
In vivo VLDL secretion in EFAD and EFAS mice. In mice fed EFAD or EFAS diet for 8 wk (n ϭ 6 per group), plasma lipolysis was blocked by retro-orbital injection of Triton WR-1339 (12.5 mg/100 l PBS) after an overnight fast. Blood samples (75 l) were obtained from the retro-orbital plexus under halothane anesthesia before and at 60-min intervals after Triton injection for 4 h. Blood was collected in micro-hematocrit tubes containing heparin, and was centrifuged at 2,400 rpm for 10 min (Eppendorf Centrifuge) for isolation of plasma and blood cells. At the end of the experiment, a large blood sample was obtained by cardiac puncture after which the liver was removed and stored at Ϫ80°C until further analysis. From the last blood sample, the plasma VLDL fraction (density 0.93-1.006 g/ml) was isolated by ultracentrifugation. For this purpose, 800 l of NaCl solution with a density of 1.006 g/ml, containing 0.02% NaN 3, was added to 200 l plasma, followed by centrifugation for 100 min at 120,000 rpm at 4°C in an Optima LX table-top centrifuge (Beckman Instruments, Palo Alto, CA). The top layer containing the VLDL fraction was isolated by tube slicing, and the volume was recorded by weight. A 30-l portion was used for particle size determination using dynamic light scattering (for details, see Analytical Techniques) and the remaining VLDL fraction was stored at Ϫ80°C until further analysis.
Postheparin HL and LPL activity in plasma of EFAD and EFAS mice. Separate groups of EFAD and EFAS mice (n ϭ 6 per group) were fasted for 4 h, after which a baseline blood sample (150 l) was obtained by orbital bleeding under halothane anesthesia for determination of baseline plasma lipase activity. Subsequently, an intravenous bolus of 0.1 U heparin/g body wt was injected, and 10 min later a postheparin blood sample (150 l) was obtained by orbital bleeding. Blood was collected in heparinized microhematocrit tubes and immediately centrifuged at 2,400 rpm for 10 min (Eppendorf Centrifuge), and isolated plasma was frozen in 10% glycerol in liquid nitrogen and stored at Ϫ80°C until in vitro analysis of LPL and HL activities (54) .
For the LPL and HL assay, 10 l of plasma was incubated with 200 l of ultrasonified substrate containing 1 ml Triton X-100 (1%), 1 ml Tris ⅐ HCl (1 M), 2 ml of heat-inactivated human serum, 2 ml of fat-free BSA (10%), 42 mg triolein and 5 l glycerol-tri-9,10(n)- [ 3 H]-oleate (5 mCi/ml), with or without addition of 50 l NaCl (5 M) to block LPL activity. After 30-min incubation at 37°C, lipolysis was stopped by adding 3.25 ml of heptane/methanol/chloroform (100:128: 137, vol/vol/vol) and 1 ml of 0.1 M K 2CO3. After centrifugation for 15 min at 3,600 rpm at room temperature, extracted hydrolyzed fatty acids were quantified by scintillation counting. Lipase activities were calculated according to the formula: [disintegrations per second (dps) sample Ϫ dps blank]/dps 200 l LPL-substrate ϫ factor, in which the factor ϭ {2.45 (volume aqueous phase) ϫ 4.74 (total added free fatty acids in micromoles)/[0.76 (extraction efficiency) ϫ 0.5 (reaction time in hours) ϫ 0.01 (plasma volume in milliters)]}. Postheparin LPL activity was calculated by subtracting postheparin HL activity (i.e., lipase activity inhibited by 1 M NaCl) from the total postheparin lipase activity.
In vitro VLDL secretion from cultured EFAD and EFAS hepatocytes. Isolation of hepatocytes from mice fed EFAD or EFAS diet for 8 wk was performed as described previously (20, 22) . Hepatocytes were plated in 35-mm six-well plastic dishes precoated with collagen (Serva Feinbiochemica, Heidelberg, Germany) at a density of 1.0 ϫ 10 6 cells per well, suspended in 2 ml of William's E medium (GIBCO-BRL, Grand Island, NY) supplemented with 10% FCS, 0.20 U/ml insulin, 100 U/ml penicillin, 100 g/ml streptomycin, 50 g/ml gentamycin, and 50 nM dexamethasone. Cells were maintained in a humidified incubator at 37°C and 5% CO 2. After a 5-h attachment period, the medium was refreshed. Cells were cultured overnight, medium was removed, and hepatocytes were washed and incubated for 4 h with hormone-free and FCS-free (HF/SF) William's E medium supplemented with 1.7% fat-free albumin, insulin, penicillin/streptomycin, and gentamycin. Medium was replaced by 1 ml HF/SF William's E medium per well containing 22 M [ 3 H]glycerol (4.4 Ci per well), 3 M glycerol, 0.75 mM oleic acid (C18:1) complexed with fatty acid-free BSA. After 24-h incubation, medium was collected and centrifuged for 2 min at 13,000 rpm to remove debris, and stored at Ϫ80°C until further analysis. Hepatocytes were washed with ice-cold HBSS and scraped into 2 ml of HBSS for lipid extraction.
Analytical Techniques
Plasma lipids were measured by using commercially available assay kits from Roche (Mannheim, Germany) for TG and total cholesterol, and from Wako Chemicals (Neuss, Germany) for PLs. ApoB protein levels were determined by Western blot analysis. Proteins from plasma VLDL fractions (10 l VLDL/lane) were separated on 4 -15% ready gels and blotted onto nitrocellulose membranes (Hybond ECL; Amersham Pharmacia Biotech) by tankblotting. Membranes were blocked overnight in a 4% skimmed milk power solution in Tris-buffered saline containing 0.1% Tween-20 (TTBS) and subsequently incubated with the primary antibody (human polyclonal anti-apoB, cross-reactive with mouse, Roche, Mannheim Germany) diluted 1:100,000 in TTBS for 2 h at room temperature. After washing, anti-sheep IgG linked to horseradish peroxidase (Calbiochem, San Diego, CA), diluted 1:10,000 in TTBS, was added for 1 h. Detection was carried out by using enhanced chemiluminescence, according to manufacturer's instructions (Amersham, Roosendaal, the Netherlands), and bands of apoB were quantified by using Image Masters video documentation system (VDS; Amersham Pharmacia Biotech).
VLDL size and volume distribution profiles were analyzed by dynamic light scattering, using a submicron particle analyzer (model 370; Nicomp Particle Sizing Systems, Santa Barbara, CA). Particle diameters were calculated from the volume distribution patterns provided by the analyzer. TG-rich lipoprotein diameters were also estimated by using the equation: diameter (nm) ϭ 60 ϫ ([0.211 ϫ TG/PL] ϩ 0.27) according to Fraser (11) and Harris et al. (17) .
EFA status was analyzed by hydrolyzing, methylating, and extracting plasma and erythrocyte lipids as described previously (35) . For fatty acid analysis of cultured hepatocytes, lipids were extracted from aliquots of mechanically homogenized cell suspensions (7) followed by methylation procedures as described above. Butylated hydroxytoluene was added as antioxidant. Heptadecanoic acid (C17:0) was added to all samples as internal standard before extraction. Fatty acid methyl esters were separated and quantified by gas liquid chromatography on a gas chromatograph equipped with a 50-m ϫ 0.2-mm Ultra 1 capillary column (model 6890; Hewlett Packard, Palo Alto, CA) and a flame ionization detector, using program conditions as described previously (48) . Individual fatty acid methyl esters were quantified by relating areas of their chromatogram peaks to that of the internal standard C17:0. Relative concentrations (%mol) of erythrocyte and hepatocyte fatty acids were calculated by summation of fatty acid peak areas and subsequent expression of the area of each individual fatty acid as a percentage of this amount.
Lipids secreted into medium by EFAD and EFAS mouse hepatocytes and cellular lipids were subjected to the lipid extraction procedure mentioned above. ]TG and -PL spots were delineated and scraped into vials and assayed for radioactivity by scintillation counting. A portion of the extracted lipids was dissolved in chloroform containing 2% Triton X-100. After chloroform evaporation and resuspension in H 2O, total cellular TG concentration was determined by using the TG assay kit mentioned above.
Protein concentrations in isolated mouse hepatocytes were determined according to Lowry et al. (29) , using Pierce BSA as standard. Secreted apoB in medium of EFAD and EFAS mouse hepatocytes was concentrated with fumed silica and delipidated as described by Vance et al. (44) ; ApoB protein was separated by SDS-PAGE using 4 -15% gradient gels at 100 V for 30 min followed by 150 V for 90 min. Subsequently, gels were subjected to the silver staining procedure as described by Curtin et al. (9) . The relative intensities of apoB100 and apoB48 bands were determined by using a chargecoupled device camera of Image Masters VDS (Amersham Pharmacia Biotech).
For measurement of mRNA expression levels by real-time PCR, total RNA from EFAD and EFAS liver tissue aliquots was isolated by using TRI reagent (cat. no. T9424; Sigma) according to the manufacturer's instructions. Isolated total RNA was converted to singlestranded cDNA with Moloney murine leukemia virus reverse transcriptase by the manufacturer's protocol (Sigma). Real-time quantitative PCR was performed by using the ABI prism 7700 sequence detector (Applied Biosystems, Foster City, CA). Primers were obtained from Invitrogen, and a template-specific 3Ј-TAMRA, 5Ј-6-FAM-labeled double dye oligonucleotide probe was obtained from Eurogentec (Seraing, Belgium). Primers and probes used in these studies for Acc1, ApoB, Fas, Mttp, Srebp1a, Srebp1c, 18S, ␤-actin, and hmgCoAS-m have been described previously (13, 21, 37) . Acc2 forward primer: 5Ј-CAT ACA CAG AGC TGG TGT TGG ACT-3Ј, reverse primer: 5Ј-CAC CAT GCC CAC CTC GTT AC-3Ј, probe: forward primer: 5Ј-CTC AGT GGG AGC GAC TCT TCA-3Ј, reverse primer: 5Ј-GGC CTC TGT GGT ACA CGA CAA-3Ј, probe: 5Ј-CCT GGG GAG GAG ACA GAC ACC ATC CAA C-3Ј, GenBank accession no. NM_013495; Cpt1b forward primer: 5Ј-CCC ATG TGC TCC TAC CAG ATG-3Ј, reverse primer: 5Ј-CAC GTG CCT GCT CTC TGA GA-3Ј, probe: 5Ј-CCC AGG CAA AGA GAC AGA CTT GCT ACA GC-3Ј, GenBank accession no. NM_009948. All expression data were subsequently standardized for ␤-actin, which was analyzed in separate runs.
Calculations and Statistics
All results are presented as means Ϯ SD for the number of animals indicated. Data were statistically analyzed by using Student's t-test or, in absence of normal distribution, by the Mann-Whitney U-test. Level of significance was set at P Ͻ 0.05. Analyses were performed by using SPSS for Windows software (Chicago, IL).
RESULTS
In previous studies (33, 48) Figure 1 shows that the EFAD diet decreased concentrations of EFA and long-chain polyunsaturated fatty acids (LCPUFA) and increased levels of non-EFA in plasma VLDL and in erythrocytes. Effects were more pronounced in VLDL than in erythrocytes. Similar to previous studies, plasma TG concentration was decreased in EFAD mice (EFAD: 0.4 Ϯ 0.1 mM, EFAS: 0.8 Ϯ 0.6 mM, P Ͻ 0.05), which was predominantly due to a decrease in the VLDL-sized lipoprotein fraction (Fig.  2) . Cholesterol concentrations were higher in fractions 15-20 of the FPLC profile of EFAD mice, which may indicate the presence of large HDL particles or increased amounts of intermediate density lipoprotein (IDL)/LDL-sized particles. Figure 3 shows that, on lipolysis blockage by Triton WR-1339, plasma accumulation of TG was similar in EFAD and EFAS mice, indicating equal VLDL-TG production rates (193 Ϯ 78 vs. 173 Ϯ 46 mol TG⅐kg Ϫ1 ⅐h Ϫ1 for EFAD and EFAS mice, respectively; not significant). Figure 4 shows that TG and PL levels in the VLDL fraction isolated 4 h after Triton administration were similar in EFAD and EFAS mice. ApoB100 concentrations in this fraction were also similar in EFAD and EFAS mice, yet apoB48 was significantly lower in VLDL of EFAD mice (Fig. 4C , P Ͻ 0.05). The decreased apoB48 concentration combined with the unaffected TG secretion rate suggests an increased size of secreted VLDL particles during EFA deficiency. Lipoprotein particle size in plasma of EFAD mice was estimated by three methods. First, the coreto-surface ratio in the isolated TG-rich lipoprotein fraction (4 h after Triton) was significantly higher in EFAD than in EFAS mice (6.6 Ϯ 0.9 vs. 4.9 Ϯ 1.2, P Ͻ 0.05, Fig. 5A ). Second, on calculation of lipoprotein diameters according to Fraser (11) and Harris et al. (17), TG-rich lipoproteins from EFAD mice similarly appeared larger than those from EFAS mice ( Fig. 5B , P Ͻ 0.05). Finally, determination of TG-rich lipoprotein size using dynamic light scattering also indicated that plasma lipoproteins from EFAD mice were larger than from EFAS mice; however, this difference did not reach statistical significance (P ϭ 0.37, Fig. 5C ).
In addition to quantifying VLDL-TG production in mice in vivo, VLDL-TG production was determined in cultured hepatocytes from EFAD and EFAS mice in vitro to exclude a possible influence of confounding metabolic effects of the systemic circulation on VLDL production. Figure 6 shows that primary hepatocytes from EFAD mice cultured for 48 h displayed the classical biochemical markers of EFA deficiency, including decreased levels of linoleic acid, ␣-linolenic acid, and their long-chain metabolites arachidonic acid and docosahexaenoic acid, and increased concentrations of non-EFAs of the n-7 and n-9 family. Biochemical indications for EFA deficiency were more pronounced in TG than in PL of hepatocytes, as described previously (47) . After 24 h of incubation with [ 3 H]glycerol and oleic acid, EFAD hepatocytes had incorporated significantly more label into TG and PL than EFAS hepatocytes, compatible with higher rates of TG and PL synthesis (Fig. 7A) . Total intracellular TG mass was approximately twofold higher in hepatocytes from EFAD mice, compared with those from EFAS mice (Fig. 7B) . Specific cellular TG activity was similar in EFAD and EFAS cells (Fig. 7C) . EFAD hepatocytes secreted similar amounts of [ 3 H]TG into the medium, but significantly less PL compared with EFAS mice (Fig. 7D) . The apoB content was lower in medium from EFAD than from EFAS cells (Fig. 7E) , indicating secretion of a decreased number of particles.
Because hepatic TG production was not affected by EFA deficiency in mice, hypotriglyceridemia is likely attributable to accelerated clearance of TG-rich lipoproteins. Determination of mRNA levels of genes involved in hepatic lipogenesis and VLDL assembly, using real-time quantitative PCR, showed a significantly increased expression in EFAD mice of Acc1, which produces malonyl-CoA for fatty acid synthesis (Fig. 8) . Expression of Fas, a critical gene for lipogenesis, tended to be higher in EFAD livers, but the difference did not reach statistical significance. Hepatic expression of Acc2, Cpt1a, and Cpt1b was significantly increased in EFAD mice, compatible with increased hepatic fatty acid oxidation. mRNA levels of ApoB and Mttp, key regulators of VLDL formation, were similar in EFAD and EFAS livers. Expression of ApoCIII, a LPL inhibitor, was similar in EFAD and EFAS mice, but mRNA levels of ApoCII and apoAV, involved in modulation of LPL activity, were significantly higher in livers of EFAD mice compared with controls. Figure 9 shows the in vitro activities of postheparin plasma HL and LPL in EFAD and EFAS mice. No significant differ- ences in either HL or LPL activities were detected between the two groups.
DISCUSSION
We previously demonstrated that EFA deficiency in mice is associated with increased hepatic and decreased plasma TG concentrations (48) . In the present study, we investigated whether decreased hepatic VLDL secretion contributes to these metabolic consequences of EFA deficiency. Our in vivo and in vitro data indicate that EFA deficiency does not affect quantitative hepatic TG secretion, but alters VLDL size and composition. We speculate that large VLDL particles, perhaps in combination with increased apoCII expression, may be subject to increased clearance rates, resulting in hypotriglyceridemia.
To test this hypothesis experimentally, clearance rates and plasma lipid levels could be measured in EFAD and EFAS Data represent mean values Ϯ SD measured in hepatocytes from 2 individual mice per group; n ϭ 6 separate measurements per mouse. *P Ͻ 0.001 for differences between EFAD and EFAS hepatocytes. B: total intracellular TG mass (mol/mg protein) in hepatocytes from EFAD and EFAS mice. Data represent mean values Ϯ SD measured in hepatocytes from 2 individual mice per group, n ϭ 6 separate measurements per mouse. *P Ͻ 0.001 for differences between EFAD and EFAS hepatocytes. C: specific cellular TG activity (dpm/nmol TG) in cultured hepatocytes from EFAD and EFAS mice (n ϭ 2 mice per group). Posts represent means Ϯ SD from 6 separate measurements per mouse, P ϭ 0.08 for EFAD vs. EFAS hepatocytes. D: [ 3 H]-TG and [ 3 H]-PL secretion into medium (dpm ϫ 10 3 /mg protein) by hepatocytes from EFAD and EFAS mice (n ϭ 2 mice per group). Data represent means Ϯ SD from 6 separate measurements per mouse. *P Ͻ 0.001 for differences between [ 3 H]-labeled PL secretion by EFAD and EFAS hepatocytes. [ 3 H]-TG levels were not significantly different between the 2 groups. E: ApoB48 and apoB100 content in medium from EFAD hepatocytes compared with that of EFAS hepatocytes (n ϭ 2 mice per group). Data represent means Ϯ SD from 6 separate measurements per mouse. *P Ͻ 0.01 for differences in apoB content in medium of EFAD and EFAS hepatocytes. mice after infusing a defined lipoprotein emulsion of labeled particles, fractionated into homogenous size populations as described by Rensen et al. (41) . Alternatively, although technically more challenging, VLDL particles could be isolated from EFAD and EFAS mice and labeled ex vivo, and then clearance rates of EFAD-derived VLDL and of EFAS-derived VLDL could be determined, each in EFAD and EFAS mice.
Fatty acid profile analyses of erythrocytes, plasma VLDL, and isolated hepatocytes confirmed the presence of EFA deficiency in our mouse model. As previously demonstrated (48) , plasma TG levels were decreased in EFAD mice, particularly in the VLDL fraction as determined by FPLC. Hepatic VLDL-TG secretion, however, was not decreased in EFAD mice in vivo (determined by Triton lipolysis blockage), or in EFAD hepatocytes (determined by [ 3 H]glycerol incorporation) in vitro. Decreased hepatic TG and PL secretion has been reported in studies with perfused livers of EFAD rats (12) . However, the isolated perfused liver model has its limitations regarding physiological lipoprotein secretion, due to lack of hormonal and metabolic feedback from the circulation, with the perfusate usually only containing erythrocytes and fatty acids. The discrepancy regarding in vivo studies on lipoprotein clearance in EFAD rats (10, 27) and our EFAD mouse model may be explained by species specificity. Previous studies have demonstrated that EFA deficiency has different effects on bile formation in rats and in mice (24, 25, 48) .
Although no quantitative differences were detected in hepatic TG secretion rates, secreted VLDL particles were significantly larger under EFAD conditions. The production of larger VLDL particles could be deduced from several independent observations. During EFA deficiency, the concentration of PL in the VLDL fraction was more profoundly decreased than that of TG (Ϫ80 vs. Ϫ50%, respectively; Fig. 2 ), indicating production of particles with increased core-to-surface ratio. The plasma VLDL fraction isolated by ultracentrifugation (after lipolysis blockage by Triton) contained less apoB48 in EFAD than in EFAS mice. Because a single apoB48 molecule is present per VLDL particle, this indicates secretion of a reduced number of VLDL particles in vivo. In line with these observations, estimations of particle size by various means also indicated that VLDL particles in EFAD mice were larger than in controls. In vitro, EFAD hepatocytes similarly secreted equal amounts of labeled TG but lower amounts of PL and apoB into the medium. An increase in VLDL particle size has previously been reported in EFAD rats (27) and EFAD guinea pigs (1, 2) . We hypothesize that during EFA deficiency, the increased concentration of saturated acyl chains of hepatic PL or the decreased concentration of unsaturated acyl chains (that is, insufficient hepatic EFA-rich PL availability) affect the surface coating of nascent lipoproteins, resulting in relative TG-oversaturation of secreted VLDL. Thus hepatic VLDL-TG secretion rates apparently are not quantitatively affected during EFA deficiency in mice. By inference, the decreased plasma TG concentration must be due to increased VLDL clearance.
Differences in VLDL clearance during EFA deficiency in mice could result from increased activities of lipolytic enzymes, such as HL and LPL. However, we found no indications that EFA deficiency affects the in vitro activities of HL or LPL in EFAD mice. Alternatively, VLDL clearance could be enhanced secondary to alterations of VLDL particles, as was also suggested by Sinclair and Collins (43) for enhanced TG clearance from plasma of EFAD rats. In EFAD mice, intravascular lipoprotein metabolism could be influenced by altered interactions with apoCII with the recently identified apoAV, or with LPL or phospholipid transfer protein (PLTP) (34, 40) . The decreased EFA content of VLDL surface-and core-lipid acyl chains, as well as the decreased PL-to-TG ratio, affects the physical structure of VLDL particles during EFAD, which could increase the affinity of binding sites for apoCII or apoAV. In addition, it could be hypothesized that a more saturated surface layer in EFAD VLDL can accommodate slightly better the appearance of TG from the core of the lipoprotein at the interface, where TG serves as substrate for lipases. Hamilton regated into the core oil phase, but is also present in small proportions (Ϯ3%) intercalated in the PL surface layer. Although the exact mechanism by which LPL gains access to VLDL-TG is not known, the surface TG, with carbonyl groups arranged at the aqueous interface, provides the main pool for interaction with lipolytic enzymes. The decreased PUFA content of lipoprotein-TG and -PL in EFAD mice may enhance incorporation of TG in the PL monolayer at the aqueous interface, thus increasing accessibility to lipases. During lipoprotein TG hydrolysis, the transfer of excess surface PL to HDL is mediated PLTP. Rao et al. (39) reported that small VLDL have less affinity for PLTP than large. The EFAD VLDL size and particle surface packing may thus affect the binding affinity for PLTP, and thereby its efficiency as a PL carrier, and VLDL metabolism.
Interestingly, both apoAV and apoCII mRNA levels were significantly increased during EFA deficiency in mice, which may be compatible with enhanced VLDL catabolism. The increased VLDL particle size could also account for increased clearance from the plasma compartment. In chylomicron studies, Quarfordt and Goodman (38) and Chajek-Shaul et al. (8) demonstrated that large particles are cleared more rapidly from plasma than small particles. Production of VLDL with a larger size implies that fewer particles are being secreted to account for the similar TG production rates. Martins et al. (30) postulated that particle number strongly affects lipoprotein clearance rate, with small numbers of particles being cleared more rapidly than large numbers, possibly due to a receptor-saturable process involving the availability of apoE.
The relationship between murine EFA deficiency and VLDL particle size may be related to the availability of PL for lipoprotein assembly. Under conditions of reduced PL availability for VLDL assembly, e.g., during choline deficiency in rats, VLDL particles with an increased core-to-surface ratio are produced (45, 53) . We speculate that a similar situation may apply in murine EFA deficiency. Previously, we (48) demonstrated that EFA deficiency in mice profoundly increases the amount of PL secreted into bile. Biliary PL are predominantly composed of phosphatidylcholine (PC), similar to PL used for VLDL assembly. The increased biliary secretion of PC into the intestine may limit the availability of PC for hepatic lipoprotein assembly, thus leading to production of VLDL particles of increased size.
In addition to decreasing plasma TG levels, EFA deficiency in mice increased hepatic TG content, both in vivo and in vitro. Interestingly, genes involved in fatty acid oxidation (Cpt1a, Cpt1b, Acc2) were upregulated in livers of EFAD mice, compatible with activation of transcription factor PPAR␣ (46) . It is well-known that EFA and LCPUFA are natural ligands for PPAR␣, and it was unexpected that PPAR␣-regulated genes were upregulated during EFA deficiency. Possibly, increased levels of non-essential LCPUFA (n-9 and n-7 family) in EFAD livers can also activate PPAR␣. Increased de novo synthesis of n-9, n-7, and saturated fatty acids from acetyl-CoA may engender increased rates of hepatic TG synthesis during EFA deficiency. Present data suggest that unimpaired VLDL-TG secretion rates, in combination with increased hepatic TG synthesis, causes hepatic TG accumulation in EFAD mice.
For speculations on the potential clinical implications of our current observations, we attempted to relate our findings on the effects of EFA deficiency on lipoprotein metabolism in mice to reports on cystic fibrosis (CF) patients in whom EFA deficiency is frequently observed. Unfortunately, no human CF data are available in which information is simultaneously provided on presence of steatosis, plasma TG concentrations, and VLDL particle size and clearance. Yet, indirect indications offer some support for extrapolation of our present findings to the human condition, although caution is warranted. Levy et al. (26) reported on the combination of hypertriglyceridemia and diminished plasma PL concentrations in EFAD CF patients compared with non-CF siblings. Interestingly, plasma VLDL of EFAD CF patients was relatively TG-enriched compared with non-CF siblings, suggestive of increased particle size of these lipoproteins in CF. However, a similar finding was reported for non-EFAD CF patients, and no data on steatosis were provided. In 1999, Lindblad et al. (28) reported that 35% of CF patients had steatosis and that the level of the EFA linoleic acid in plasma PL negatively correlated with the degree of steatosis.
We conclude that the steatosis and hypotriglyceridemia during EFA deficiency in mice is a combined result of unimpaired hepatic TG secretion, increased hepatic synthesis of non-EFAs and secretion of large VLDL particles, which may be subject to rapid clearance rates.
